Entries by CAPTIS

The partnership between Boehringer Ingelheim and Lupin will develop LNP3794 as a potential targeted therapy for patients with difficult-to-treat cancers. The companies will develop the MEK inhibitor compound The post Boehringer Ingelheim signs £574m deal for Lupin’s MEK inhibitor compound appeared first on Pharmaceutical Business review.

STOP-301 is evaluating the safety of long-term, intermittent use of INP104 for 24-week and 52-week data points and will also collect efficacy data of INP104 as assessed by The post Impel NeuroPharma enrolls last patient in phase 3 migraine trial of INP104 appeared first on Pharmaceutical Business review.

Vertex Pharmaceuticals has agreed to acquire US-based biotech company Semma Therapeutics for $950m (£784.66m) in an all-cash deal with an aim to develop curative cell-based treatments for type The post Vertex to acquire US biotech firm Semma Therapeutics for £785m appeared first on Pharmaceutical Business review.

The Maryland-based Insilico Medicine claimed that GENTRL can fast track the drug discovery process from years to days. The company is said to have validated the AI technology The post Insilico Medicine develops AI-based drug discovery platform appeared first on Pharmaceutical Business review.

A cannula is a thin, flexible tube with a rounded tip that can serve as an effective delivery system. Use of a cannula allows for injection of Juvéderm The post Allergan receives FDA approval of Juvéderm VOLUMA XC for mid-face injection appeared first on Pharmaceutical Business review.

Results suggest that Entresto, an essential treatment for HFrEF, not only positively impacts a biomarker shown to be associated with prognosis of clinical outcomes in HFrEF, but also The post Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study appeared first on Pharmaceutical Business review.

Topline data from the study were published on 3 July 20191, which showed a significant reduction in hyperglycemia, body weight and waist size compared to placebo. The entire The post VALBIOTIS announces additional positive results from phase IIA clinical study of VALEDIA appeared first on Pharmaceutical Business review.

Anifrolumab has demonstrated a statistically-significant and clinically-meaningful reduction in disease activity compared to placebo in the trial. Both arms received standard of care in the study. Anifrolumab is The post AstraZeneca’s anifrolumab meets primary endpoint in phase III SLE trial appeared first on Pharmaceutical Business review.

The late-stage trials – ASCLEPIOS I and II probed the efficacy and safety of ofatumumab 20mg given as a once-monthly subcutaneous injection, in comparison to daily once oral The post Novartis’ ofatumumab meets primary endpoints in two phase 3 RMS trials appeared first on Pharmaceutical Business review.

The phase III trial has demonstrated that Xofluza was a well-tolerated and efficient potential treatment for flu in otherwise healthy children aged one to less than 12 years The post Roche’s one-dose Xofluza meets primary endpoint in phase III flu study of children appeared first on Pharmaceutical Business review.

Leveraging artificial intelligence & machine learning in the right way at the right time is key to our technology approach in R&D. Find out more from Tony Wood, SVP for Medicinal Science & Tech, and other experts on their real-world use of #AI. twitter.com/endpts/s…

Are you attending #GHC19 – the world’s largest gathering of women technologists? Stop by Stryker’s booth to learn more about our engineering opportunities & how you can work with products that are making healthcare & people’s lives better! bit.ly/2KICViN#WeAreStrykerpic.twitter.com/rFE1…